TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1182/BLOOD-2004-03-1196PMID 15213096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RANK ligand and osteoprotegerin in myeloma bone disease.

  2003cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Apo2L/TRAIL and its death and decoy receptors

  2003cited by this paper
• TWEAK Mediates Signal Transduction and Differentiation of RAW264.7 Cells in the Absence of Fn14/TweakR

  2003cited by this paper
• Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.

  2003cited by this paper
• Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.

  2003cited by this paper
• p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function.

  2002cited by this paper
• Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

  2002cited by this paper
• The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.

  2002cited by this paper
• Characterization of the in vivo function of TNF‐α‐related apoptosis‐inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene‐deficient mice

  2002cited by this paper
• Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways* 210

  2002cited by this paper
• U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells*

  2002cited by this paper
• Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.

  2001cited by this paper
• Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

  2001cited by this paper
• Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)--mediated cytotoxicity by selective up-regulation of TRAIL-R1.

  2001cited by this paper
• Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways *

  2001cited by this paper
• TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

  2001cited by this paper
• TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

  2001cited by this paper
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

  2001cited by this paper
• Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

  2001cited by this paper
• Temperature-sensitive Differential Affinity of TRAIL for Its Receptors

  2000cited by this paper
• Characterization of osteoclast precursors in human blood

  2000cited by this paper
• Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation.

  2000cited by this paper
• Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction

  2000cited by this paper
• RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

  2000cited by this paper
• Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)*

  2000cited by this paper
• TGF-β1 and IFN-γ Direct Macrophage Activation by TNF-α to Osteoclastic or Cytocidal Phenotype1

  2000cited by this paper
• Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL).

  2000cited by this paper
• TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.

  2000cited by this paper
• TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytocidal phenotype.

  2000cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

  1999cited by this paper
• Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

  1999cited by this paper
• Human osteoclasts derive from CD14‐positive monocytes

  1999cited by this paper
• IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.

  1998cited by this paper
• Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

  1997cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells*

  1997cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper
• Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

  1990cited by this paper

• Characteristics of osteoclasts at different developmental stages and therapeutic strategies.

  2026cites this paper
• LGR4 binding small RANKL fragment inhibits RANKL-induced bone resorption

  2025cites this paper
• Dectin-2 depletion alleviates osteoclast-induced bone loss in periodontitis via Syk/NOX2/ROS signaling.

  2025cites this paper
• Curcumin Ameliorated Glucocorticoid-Induced Osteoporosis While Modulating the Gut Microbiota and Serum Metabolome.

  2025cites this paper
• Osteoimmunology and aging: Mechanisms, implications, and therapeutic perspectives.

  2025cites this paper
• Potential Biological and Genetic Links Between Dementia and Osteoporosis: A Scoping Review

  2025cites this paper
• Immunomodulatory Functions of TNF-Related Apoptosis-Inducing Ligand in Type 1 Diabetes

  2024cites this paper
• Biomaterial Cues for Regulation of Osteoclast Differentiation and Function in Bone Regeneration

  2024cites this paper
• Innate lymphoid cells: New players in osteoimmunology

  2024cites this paper
• Unveiling thioacetamide-induced toxicity: Multi-organ damage and omitted bone toxicity

  2024cites this paper
• AdipoAI suppresses osteoclastogenesis by activating AdipoR1/APPL1: An in vivo experimental study in diabetes-associated peri-implantitis.

  2023cites this paper
• Hyperuricemia remodels the serum proteome toward a higher inflammatory state

  2023cites this paper
• The dual role of autophagy in periprosthetic osteolysis

  2023cites this paper
• Circulating Monocytes Act as a Common Trigger for the Calcification Paradox of Osteoporosis and Carotid Atherosclerosis via TGFB1-SP1 and TNFSF10-NFKB1 Axis

  2022cites this paper
• Functional characterization of a putative Tumor Necrosis Factor Superfamily Member 10 in blood clam (Tegillarca granosa).

  2021cites this paper
• The multifaceted role of TRAIL signaling in cancer and immunity

  2020cites this paper
• Ca2+/CaM/CaMK signaling is involved in cadmium-induced osteoclast differentiation.

  2020cites this paper
• TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment

  2019cites this paper
• Eldecalcitol effects on osteoblastic differentiation and function in the presence or absence of osteoclastic bone resorption

  2019cites this paper
• Type I interferons and endoplasmic reticulum stress in health and disease

  2019cites this paper
• Positive and negative regulators of osteoclast apoptosis

  2019cites this paper
• Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli

  2019cites this paper
• Mechanisms Involved in Childhood Obesity-Related Bone Fragility

  2019cites this paper
• Effect of the needles with different nanostructured carbon coatings on the osteoporotic bone tissue in the experiment

  2019cites this paper
• Roles of SP600125 in expression of JNK, RANKL and OPG in cultured dental follicle cells

  2019cites this paper
• Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors

  2018cites this paper
• Nano-sized Al2O3 particle-induced autophagy reduces osteolysis in aseptic loosening of total hip arthroplasty by negative feedback regulation of RANKL expression in fibroblasts

  2018cites this paper
• In vitro cell models of vascular calcification: integrative roles for RANKL and TRAIL

  2018cites this paper
• The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease

  2018cites this paper
• An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis

  2018cites this paper
• TRAIL attenuates RANKL-mediated osteoblastic signalling in vascular cell mono-culture and co-culture models

  2017cites this paper
• Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis

  2017cites this paper
• TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.

  2017cites this paper
• Cell death‐independent activities of the death receptors CD95, TRAILR1, and TRAILR2

  2017cites this paper
• Identification, characterization and bioactivity of tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand from Equus caballus

  2017cites this paper
• Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.

  2016cites this paper
• The beneficial pleiotropic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) within the vasculature: A review of the evidence.

  2016cites this paper
• Clinical perspectives of TRAIL: insights into central nervous system disorders

  2016cites this paper
• TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors

  2016cites this paper
• Running title: Nutlin-3 upregulates Notch1 expression

  2016cites this paper
• STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells.

  2015cites this paper
• TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications

  2015cites this paper
• Contribution of osteoclasts to the bone–tumor niche

  2015cites this paper
• A comparative study of bone remodeling molecules expression in different types of jaw ameloblastoma.

  2015cites this paper
• Metabolic bone disorders: from bench to bedside

  2014cites this paper
• Wybrane czynniki proapoptotyczne i antyapoptotyczne w młodzieńczym idiopatycznym zapaleniu stawów

  2014cites this paper
• Serum levels of M-CSF, RANKL and OPG in rats fed with Kashin-Beck disease-affected diet

  2014cites this paper
• Expression of TRAIL and its receptors DR5 and DcR2 in orthodontic tooth movement.

  2013cites this paper
• TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.

  2013cites this paper
• The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis.

  2013cites this paper
• Moutan Cortex Radicis inhibits inflammatory changes of gene expression in lipopolysaccharide-stimulated gingival fibroblasts

  2013cites this paper
• Real-time activity bioassay of single osteoclasts using a silicon nanocrystal-impregnated artificial matrix.

  2013cites this paper
• Periodontal Disease: Linking the Primary Inflammation to Bone Loss

  2013cites this paper
• TRAIL-Deficiency Accelerates Vascular Calcification in Atherosclerosis via Modulation of RANKL

  2013cites this paper
• Correction: TRAIL-Deficiency Accelerates Vascular Calcification in Atherosclerosis via Modulation of RANKL

  2013cites this paper
• Molecular mechanisms underlying staphylococcal induced osteomyelitis.

  2012cites this paper
• RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

  2012cites this paper
• TRAIL effect on osteoclast formation in physiological and pathological conditions.

  2011influential citation
• Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors

  2011cites this paper
• Enhancement of TRAIL-Mediated Apoptosis by Genistein in Human Hepatocellular Carcinoma Hep3B Cells: Roles of p38 MAPK Signaling Pathway

  2011cites this paper
• Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro

  2011cites this paper
• Dexamethasone counteracts the anti‐osteoclastic, but not the anti‐leukemic, activity of TNF‐related apoptosis inducing ligand (TRAIL)

  2010cites this paper
• Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

  2010cites this paper
• Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation.

  2010cites this paper
• New insights into apoptosis signaling by Apo2L/TRAIL

  2010cites this paper
• Clathrin-dependent endocytosis of membrane-bound RANKL in differentiated osteoclasts

  2010cites this paper
• Interaction of staphylococci with bone

  2010cites this paper
• Pathway-Based Association Analyses Identified TRAIL Pathway for Osteoporotic Fractures

  2010cites this paper
• Nutlin-3 upregulates the expression of Notch 1 in both myeloid and lymphoid leukemic cells , as part of a negative feedback anti-apoptotic mechanism Running title : Nutlin-3 upregulates Notch 1 expression

  2009cites this paper
• Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.

  2009cites this paper
• Role of full-length osteoprotegerin in tumor cell biology

  2009cites this paper
• Selection and Characterization of a Novel Agonistic Human Recombinant Anti-Trail-R2 Minibody with Antileukemic Activity

  2009cites this paper
• CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation.

  2009cites this paper
• Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma

  2009cites this paper
• Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells.

  2009cites this paper
• Osteoclast apoptosis : Role of TRAIL and its receptors

  2009cites this paper
• [Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy].

  2009cites this paper
• Human Full-Length Osteoprotegerin Induces the Proliferation of Rodent Vascular Smooth Muscle Cells both in vitro and in vivo

  2009cites this paper
• Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone)

  2009cites this paper
• Is TRAIL the holy grail of cancer therapy?

  2009cites this paper
• Effect of recombinant TRAIL in a murine co-culture system of osteoclastogenesis.

  2009cites this paper
• Apo 2 L / TRAIL Inhibits Tumor Growth and Bone Destruction in aMurineModel of Multiple Myeloma

  2009cites this paper
• Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

  2009cites this paper
• Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin

  2008cites this paper
• Differential effects of chemotherapeutic drugs versus the MDM‐2 antagonist nutlin‐3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B‐cells

  2008cites this paper
• Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?

  2008cites this paper
• The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis.

  2008cites this paper
• Is there any role for tumour necrosis factor related apoptosis inducing ligand–osteoprotegerin (TRAIL–OPG) interaction in rheumatoid arthritis?

  2008cites this paper
• Tumor Necrosis Factor‐Related Apoptosis‐Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells

  2008cites this paper
• The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.

  2008cites this paper
• The 4–1BB ligand and 4–1BB expressed on osteoclast precursors enhance RANKL‐induced osteoclastogenesis via bi‐directional signaling

  2008cites this paper
• The death ligand TRAIL in diabetic nephropathy.

  2008cites this paper
• Potential involvement of TRAIL in Treg cell-mediated osteoclast suppression: comment on the article by Zaiss et al.

  2008cites this paper
• Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway

  2008cites this paper
• TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors

  2008cites this paper
• Role of TRAIL in osteoclastogenesis

  2008cites this paper
• TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells.

  2008cites this paper
• Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Modulates the Expression of Genes Involved in Apoptosis and Cell Cycle in Human Osteoclasts

  2007cites this paper
• Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus

  2007cites this paper
• RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV‐1‐positive men

  2007cites this paper